


SCARD Pool report for 01-01-2018 to 31-12-2018

| | | | |
|---------------------|-----------------------------|---------|---------|
| Participants | Doctors | 428 | |
| | Patients | 58,277 | |
| Specimens | New lesions | 109,690 | 84.88% |
| | Previously biopsied lesions | 19,536 | 15.12% |
| | Total lesions | 129,226 | 100.00% |

Breakdown of new versus previously biopsied specimens


| | |
|--|--------|
| Percentage of new lesions tested which were malignant | 62.09% |
| Percentage of Definitively excised lesions that were malignant | 81.39% |
| Lesions tested to find one melanoma (NNT) | 4.50 |
| Percentage of lesions tested for NMSC which were NMSC | 80.60% |
| Ratio of New BCCs : New Melanomas | 10:1 |

Accuracy
Diagnostic sensitivity

| | |
|-----------|------------------|
| Melanomas | 73.68% of 3,427 |
| All NMSC | 95.71% of 61,509 |
| BCCs | 91.90% of 33,188 |
| SCCs | 82.60% of 27,948 |

Positive predictive value



| | |
|-----------|------------------|
| Melanomas | 43.67% of 5,782 |
| All NMSC | 86.60% of 67,973 |
| BCCs | 44.87% of 67,973 |
| SCCs | 64.93% of 35,553 |

Adequacy
Percentage of definitively managed malignant cases where surgical margins were adequate

| | |
|---------------------------|------------------|
| BCC | 88.12% of 23,290 |
| IEC/Bowens disease | 82.42% of 5,101 |
| SCC | 87.86% of 8,284 |
| Keratoacanthoma | 91.53% of 885 |
| Melanoma - in situ | 77.43% of 2,331 |
| Melanoma - invasive | 73.03% of 597 |
| Melanoma - invasive > 1mm | 37.35% of 83 |
| Other malignant | 54.95% of 91 |

Lesion Breakdown
Histological Diagnosis

| | | |
|-----------------------------|--------|--------|
| BCC (unspecified type) | 56 | 0.05% |
| BCC - Superficial | 10,164 | 9.26% |
| BCC - Nodular/Solid | 17,699 | 16.12% |
| BCC - Aggressive | 5,269 | 4.80% |
| IEC/Bowens disease | 14,397 | 13.11% |
| SCC | 12,235 | 11.14% |
| Keratoacanthoma | 1,316 | 1.20% |
| Pinkus Fibroepithelioma | 15 | 0.01% |
| Merkel cell tumour | 15 | 0.01% |
| Other malignant | 153 | 0.14% |
| NMSC Metastasis | 4 | 0.00% |
| Melanoma - in situ | 2,506 | 2.28% |
| Melanoma - invasive | 690 | 0.63% |
| Melanoma - invasive > 1mm | 194 | 0.18% |
| Melanoma - metastasis | 37 | 0.03% |
| MELTUMP | 186 | 0.17% |
| Naevus - other | 6,118 | 5.57% |
| Naevus - dysplastic/Clark | 3,474 | 3.16% |
| Naevus - blue | 338 | 0.31% |
| Naevus - Spitz/Reed | 125 | 0.11% |
| Naevus - Compound | 0 | 0% |
| Solar keratosis | 10,354 | 9.43% |
| Solar lentigo | 1,313 | 1.20% |
| Seborrhoeic keratosis | 5,460 | 4.97% |
| Lentigo Simplex | 0 | 0% |
| Lichenoid keratosis (LPLK) | 1,984 | 1.81% |
| Dermatofibroma | 785 | 0.71% |
| Sebaceous gland hyperplasia | 233 | 0.21% |
| Benign cyst | 1,809 | 1.65% |
| Other benign | 7,331 | 6.68% |
| Histology Pending | 107 | 0.10% |



Procedures
Definitive Surgical Management used to exclude melanoma

| | | |
|-----------------------|-------|--------|
| Ellipse | 2,736 | 83.52% |
| Flap | 67 | 2.05% |
| Graft - SSG | 7 | 0.21% |
| Graft - FTSG | 14 | 0.43% |
| No Closure | 10 | 0.31% |
| Shave/Saucerisation | 118 | 3.60% |
| Curettage & Cautery | 24 | 0.73% |
| Liquid N2 freeze/thaw | 4 | 0.12% |
| PDT | 2 | 0.06% |
| Imiquimod | 1 | 0.03% |
| 5 FU cream | 1 | 0.03% |
| GP referral | 190 | 5.80% |
| Specialist referral | 66 | 2.01% |
| Other | 31 | 0.95% |

Biopsy used to exclude melanoma

| | | |
|-----------------|-------|--------|
| Punch - sample | 815 | 6.42% |
| Shave - sample | 1,068 | 8.42% |
| Incisional | 226 | 1.78% |
| Punch - removal | 2,450 | 19.31% |
| Shave - removal | 3,066 | 24.17% |
| Excisional | 5,029 | 39.64% |
| Curettage | 22 | 0.17% |
| Other | 10 | 0.08% |

Breakdown of definitive management procedures for malignant conditions

| | | |
|-----------------------|--------|--------|
| Ellipse | 34,229 | 61.77% |
| Flap | 5,264 | 9.50% |
| Graft - SSG | 360 | 0.65% |
| Graft - FTSG | 1,335 | 2.41% |
| No Closure | 306 | 0.55% |
| Shave/Saucerisation | 934 | 1.69% |
| Curettage & Cautery | 6,370 | 11.50% |
| Liquid N2 freeze/thaw | 800 | 1.44% |
| PDT | 122 | 0.22% |
| Imiquimod | 571 | 1.03% |
| 5 FU cream | 1,349 | 2.43% |
| GP referral | 1,500 | 2.71% |
| Specialist referral | 1,419 | 2.56% |
| Other | 293 | 0.53% |

Breakdown of definitive management procedures for benign conditions

| | | |
|-----------------------|-------|--------|
| Ellipse | 5,111 | 72.56% |
| Flap | 83 | 1.18% |
| Graft - SSG | 2 | 0.03% |
| Graft - FTSG | 9 | 0.13% |
| No Closure | 36 | 0.51% |
| Shave/Saucerisation | 599 | 8.50% |
| Liquid N2 freeze/thaw | 180 | 2.56% |
| 5 FU cream | 122 | 1.73% |
| GP referral | 165 | 2.34% |
| Specialist referral | 52 | 0.74% |
| Other | 142 | 2.02% |

Procedures (continued)

Percentage of procedures/closures that were complex

| | |
|--|-----------------|
| Complex Closures | 0.94% of 9,953 |
| Complex Closures (inc Curettage & Cautery) | 0.90% of 10,454 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| | | |
|---------------|------|-----------------|
| Nose | 35 | 0.54% of 6,521 |
| Lip | 8 | 0.44% of 1,810 |
| Ear | 83 | 1.78% of 4,674 |
| Eyelid | 3 | 0.26% of 1,160 |
| Other face | 330 | 1.79% of 18,453 |
| Scalp | 74 | 1.81% of 4,087 |
| Neck | 162 | 3.00% of 5,408 |
| Shoulder | 264 | 5.12% of 5,155 |
| Chest | 174 | 2.70% of 6,445 |
| Abdomen | 68 | 5.16% of 1,319 |
| Genitalia | 1 | 0.90% of 111 |
| Back | 1073 | 6.78% of 15,835 |
| Buttock | 10 | 3.70% of 270 |
| Arm | 386 | 5.93% of 6,509 |
| Forearm | 200 | 2.31% of 8,646 |
| Hand Dorsal | 7 | 0.15% of 4,704 |
| Hand Palmar | 0 | 0% of 50 |
| Finger Dorsal | 1 | 0.12% of 867 |
| Finger Nail | 2 | 12.50% of 16 |
| Finger Palmar | 0 | 0% of 20 |
| Thigh | 174 | 5.41% of 3,216 |
| Leg | 339 | 2.57% of 13,191 |
| Foot Dorsal | 21 | 2.27% of 925 |
| Foot Plantar | 6 | 5.26% of 114 |
| Toe Dorsal | 5 | 3.57% of 140 |
| Toe Nail | 0 | 0% of 8 |
| Toe Plantar | 1 | 4.17% of 24 |
| Palm Or Sole | 0 | 0% of 0 |

